Calcified Tissue International

, Volume 82, Issue 5, pp 341–347

Determinants of Bone Turnover Markers in Healthy Premenopausal Women

  • Silvano Adami
  • Gerolamo Bianchi
  • Maria Luisa Brandi
  • Sandro Giannini
  • Sergio Ortolani
  • Ombretta DiMunno
  • Bruno Frediani
  • Maurizio Rossini
  • On behalf of the BONTURNO study group
Article

Abstract

Bone turnover markers (BTMs) are widely used for the management of osteoporosis, and the premenopausal reference range is the target value for the treatment of postmenopausal osteoporosis with antiresorbing agents. Three serum BTMs (serum C-telopeptide of type I collagen [CTX], osteocalcin [OC], and N-terminal propeptide of type I procollagen [P1NP]), serum calcium, creatinine, phosphate, magnesium, and follicle-stimulating hormone (FSH) were measured in 638 healthy premenopausal women aged 20–50 years. In 83 women on the contraceptive pill (CP), the levels of the three BTMs adjusted for all confounding factors were 14–26% lower (P < 0.005) than in non-CP users. In 18 women considered perimenopausal for serum FSH levels >30 IU/mL despite having regular menses, BTM levels were significantly higher than in age-matched women. This group of subjects and the women on the CP were excluded from further analysis. The three BTMs significantly decreased with advancing age and were negatively and independently correlated with body mass index (P < 0.001) and serum phosphate. In conclusion, we confirm that CP use is associated with significantly lower BTM values. An increase in BTM concentrations can be observed in perimenopausal women, i.e., women with normal menses but FSH levels >30 IU/mL. BTMs decrease substantially with advancing age, and this appears to be associated with changes in body weight and serum phosphate. New normative ranges for serum OC, CTX, and P1NP were identified; and our findings in general impose a redefinition of the criteria for establishing the normal ranges for BTMs.

Keywords

Bone turnover marker Normative value Contraceptive pill Body weight Serum phosphate 

References

  1. 1.
    EMEA–CHMP (2007) Guidelines on the evaluation of new medicinal products in the treatment of primary osteoporosis. http://www.emea.europa.eu/pdfs/human/ewp/055295en.pdf. Accessed 7 September 2007
  2. 2.
    Melton LJ III, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227–1233PubMedGoogle Scholar
  3. 3.
    Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C (1996) Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 19:9–12PubMedCrossRefGoogle Scholar
  4. 4.
    Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11 Suppl 6:S55–S65PubMedCrossRefGoogle Scholar
  5. 5.
    Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922–930PubMedCrossRefGoogle Scholar
  6. 6.
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRefGoogle Scholar
  7. 7.
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRefGoogle Scholar
  8. 8.
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRefGoogle Scholar
  9. 9.
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337–349PubMedCrossRefGoogle Scholar
  10. 10.
    Srivastava AK, Vliet EL, Lewiecki EM, Maricic M, Abdelmalek A, Gluck O et al (2005) Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 21:1015–1026PubMedCrossRefGoogle Scholar
  11. 11.
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2–S17PubMedCrossRefGoogle Scholar
  12. 12.
    Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30–S44PubMedCrossRefGoogle Scholar
  13. 13.
    Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Oteoporos Int 14:577–582CrossRefGoogle Scholar
  14. 14.
    De Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E et al (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222–1230PubMedCrossRefGoogle Scholar
  15. 15.
    Garnero P, Sornay-Rendu E, Delmas PD (1995) Decreased bone turnover in oral contraceptive users. Bone 16:499–503PubMedCrossRefGoogle Scholar
  16. 16.
    Paoletti AM, Orru M, Floris S, Mannias M, Vacca AM, Ajossa S et al (2000) Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception 61:259–263PubMedCrossRefGoogle Scholar
  17. 17.
    Nappi C, Di Spiezio Sardo A, Acunzo G, Bifulco G, Tommaselli GA et al (2003) Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 67:355–359PubMedCrossRefGoogle Scholar
  18. 18.
    Gundberg CM, Looker AC, Nieman SD, Calvo MS (2002) Patterns of osteocalcin and bone alkaline phosphatase by age, gender, and race or ethnicity. Bone 31:703–708PubMedCrossRefGoogle Scholar
  19. 19.
    Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694–702PubMedGoogle Scholar
  20. 20.
    Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD (2001) Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16:1642–1650PubMedCrossRefGoogle Scholar
  21. 21.
    Khosla S, Melton LJ III, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274PubMedCrossRefGoogle Scholar
  22. 22.
    Hammerman MR, Karl IE, Hruska KA (1980) Regulation of canine renal vescicle Pi transport by growth hormone and parathyroid hormone. Biochem Biophys Acta 603:322–335PubMedCrossRefGoogle Scholar
  23. 23.
    Amin S, Riggs BL, Melton LJ III, Achenbach SJ, Atkinson EJ, Khosla S (2007) High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res 22:799–807PubMedCrossRefGoogle Scholar
  24. 24.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151PubMedCrossRefGoogle Scholar
  25. 25.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215PubMedCrossRefGoogle Scholar
  26. 26.
    Reginster JY, Wilson KM, Dumont E, Bonvoisin B, Barrett J (2005) Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. J Clin Endocrinol Metab 90:5018–5024PubMedCrossRefGoogle Scholar
  27. 27.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:238–243CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Silvano Adami
    • 1
  • Gerolamo Bianchi
    • 2
  • Maria Luisa Brandi
    • 3
  • Sandro Giannini
    • 4
  • Sergio Ortolani
    • 5
  • Ombretta DiMunno
    • 6
  • Bruno Frediani
    • 7
  • Maurizio Rossini
    • 1
  • On behalf of the BONTURNO study group
    • 8
  1. 1.Rheumatology UnitUniversity of VeronaValeggioItaly
  2. 2.Rheumatology UnitAzienda Sanitaria 3GenovaItaly
  3. 3.Endocrine UnitUniversity of FlorenceFlorenceItaly
  4. 4.Internal MedicineUniversity of PaduaPaduaItaly
  5. 5.Ospedale Auxologico, Milan, Unità Operativa di Reumatologia e Malattie del Metabolismo OsseoIstituto Auxologico Italiano IrccsMilanItaly
  6. 6.Rhematology UnitUniversity of PisaPisaItaly
  7. 7.Rhematology UnitUniversity of SienaSienaItaly
  8. 8.VeronaItaly

Personalised recommendations